Gupta, Ajay K

List of Publications by Year
in descending order

52 papers	2,422 citations	394421 19 h-index	233421 45 g-index
53 all docs	53 docs citations	53 times ranked	4058 citing authors

#	Article	IF	Citations
1	Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents. Hypertension, 2010, 55, 399-407.	2.7	579
2	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324â€˜168 participants from randomised trials. Lancet Oncology, The, 2011, 12, 65-82.	10.7	332
3	Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trialâ€"Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet, The, 2017, 389, 2473-2481.	13.7	279
4	Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). Journal of Hypertension, 2011, 29, 2004-2013.	0.5	147
5	Determinants of New-Onset Diabetes Among 19,257 Hypertensive Patients Randomized in the Anglo-Scandinavian Cardiac Outcomes Trialâ€"Blood Pressure Lowering Arm and the Relative Influence of Antihypertensive Medication. Diabetes Care, 2008, 31, 982-988.	8.6	142
6	The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. European Heart Journal, 2011, 32, 2525-2532.	2.2	110
7	Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet, The, 2018, 392, 1127-1137.	13.7	87
8	Role of phytosterols in lipid-lowering: current perspectives. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 301-308.	0.5	85
9	The Efficacy and Tolerability of â€˜Polypillsâ€™: Meta-Analysis of Randomised Controlled Trials. PLoS ONE, 2012, 7, e52145.	2.5	74
10	Ethnic Differences in Blood Pressure Response to First and Second-Line Antihypertensive Therapies in Patients Randomized in the ASCOT Trial. American Journal of Hypertension, 2010, 23, 1023-1030.	2.0	72
11	Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500Â000 patients with Type 2 diabetes mellitus. European Heart Journal, 2019, 40, 2899-2906.	2.2	59
12	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncology, The, 2021, 22, 558-570.	10.7	56
13	Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the JAHA Editors. Journal of the American Heart Association, 2020, 9, e017013.	3.7	52
14	COVID-19: Causes of anxiety and wellbeing support needs of healthcare professionals in the UK: A cross-sectional survey. Clinical Medicine, 2021, 21, 66-72.	1.9	41
15	Over 1000 genetic loci influencing blood pressure with multiple systems and tissues implicated. Human Molecular Genetics, 2019, 28, R151-R161.	2.9	39
16	Metabolic Syndrome, Independent of Its Components, Is a Risk Factor for Stroke and Death But Not for Coronary Heart Disease Among Hypertensive Patients in the ASCOT-BPLA. Diabetes Care, 2010, 33, 1647-1651.	8.6	37
17	Antral resection versus antral preservation during laparoscopic sleeve gastrectomy for severe obesity: Systematic review and meta-analysis. Surgery for Obesity and Related Diseases, 2018, 14, 857-864.	1.2	37
18	Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clinical Research in Cardiology, 2017, 106, 58-68.	3.3	23

#	Article	IF	Citations
19	Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14â€ƒ120 hypertensive patients of ASCOTâ€BPLA: comparison of their relative predictability using a novel approach. Diabetic Medicine, 2011, 28, 941-947.	2.3	20
20	Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). European Heart Journal, 2012, 33, 2970-2979.	2.2	14
21	ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. Journal of Human Hypertension, 2013, 27, 492-496.	2.2	14
22	Malignant Hypertension: Current Perspectives and Challenges. Journal of the American Heart Association, 2022, 11, e023397.	3.7	14
23	Implementation of depression screening in antenatal clinics through tablet computers: results of a feasibility study. BMC Medical Informatics and Decision Making, 2017, 17, 59.	3.0	13
24	Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. Journal of the American Heart Association, 2018, 7, .	3.7	13
25	Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension. American Journal of Cardiovascular Drugs, 2019, 19, 313-323.	2.2	9
26	Early and Mid-Term Implications of the COVID-19 Pandemic on the Physical, Behavioral and Mental Health of Healthcare Professionals: The CoPE-HCP Study Protocol. Frontiers in Psychology, 2021, 12, 616280.	2.1	7
27	Long-Term Incidence of Stroke and Dementia in ASCOT. Stroke, 2021, 52, 3088-3096.	2.0	7
28	Tablet computers for implementing NICE antenatal mental health guidelines: protocol of a feasibility study. BMJ Open, 2016, 6, e009930.	1.9	6
29	COVID-19 and the Digitalisation of Cardiovascular Training and Educationâ€"A Review of Guiding Themes for Equitable and Effective Post-graduate Telelearning. Frontiers in Cardiovascular Medicine, 2021, 8, 666119.	2.4	6
30	JAHA Spotlight on Air Pollution and Cardiovascular Disease: A Call for Urgent Action. Journal of the American Heart Association, 2021, 10, e022209.	3.7	5
31	Inorganic nitrate attenuates cardiac dysfunction: roles for xanthine oxidoreductase and nitric oxide. British Journal of Pharmacology, 2022, 179, 4757-4777.	5.4	5
32	Pollutants Source Control and Health Effects. Journal of Environmental and Public Health, 2013, 2013, 1-2.	0.9	4
33	Solar UV Radiation: A Potential Modifiable Risk Factor for Hypertension. Journal of the American Heart Association, 2020, 9, e015627.	3.7	4
34	LONG TERM BENEFITS OF BLOOD PRESSURE TREATMENT ON THE INCIDENCE OF ATRIAL FIBRILLATION, HEART FAILURE AND CARDIOVASCULAR MORBIDITY AND MORTALITY: 20-YEARS FOLLOW-UP OF ASCOT-LEGACY. Journal of Hypertension, 2021, 39, e8.	0.5	4
35	Role of plasma extracellular vesicles in prediction of cardiovascular risk and alterations in response to statin therapy in hypertensive patients. Journal of Hypertension, 2022, 40, 1522-1529.	0.5	4
36	The Concept of the Metabolic Syndrome. Journal of the American College of Cardiology, 2010, 56, 1355-1356.	2.8	3

#	Article	IF	Citations
37	Childhood Obesity: Today and Tomorrowâ€™s Health Challenge. Journal of Obesity, 2013, 2013, 1-2.	2.7	3
38	Equity, Diversity, and Inclusiveness in Cardiovascular Medicine and Health Care. Journal of the American Heart Association, 2020, 9, e019137.	3.7	3
39	The efficacy and cost-effectiveness of statins in low-risk patients. Cmaj, 2011, 183, 1821-1823.	2.0	2
40	LBOS 01-04 THE TRUE INCIDENCE OF STATIN -RELATED ADVERSE EVENTS IN HYPERTENSIVE PATIENTS REVEALED BY COMPARISON OF BLINDED AND UN-BLINDED USE OF STATIN IN THE ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL (ASCOT). Journal of Hypertension, 2016, 34, e547-e548.	0.5	2
41	Concerns related to the nocebo effect â€“ Authors' reply. Lancet, The, 2017, 390, 1832.	13.7	2
42	Impact of the New ACC/AHA and ESC/ESH Hypertension Guidelines in the UK. European Heart Journal, 2019, 40, 2472-2475.	2.2	2
43	THE RELATIONSHIP BETWEEN BP-CONTROL, BP -VARIABILITY AND ANTIHYPERTENSIVE TREATMENT WITH THE LONG-TERM RISK OF CARDIOVASCULAR EVENT: LESSONS FROM THE ASCOT-LEGACY 20 YEAR FOLLOW-UP. Journal of Hypertension, 2021, 39, e148.	0.5	2
44	Antihypertensive-Associated Incident Diabetes: Controversy Persists. Archives of Internal Medicine, 2007, 167, 1433.	3.8	1
45	Hypertensive Disorders in Pregnancy and the Risk of Cardiovascular Disease: A Need for Postpartum Strategies for the Primary Prevention. Journal of the American Heart Association, 2018, 7, .	3.7	1
46	Diversity, Equity, and Inclusiveness in Medicine and Cardiology: Next Steps for JAHA. Journal of the American Heart Association, 2020, 9, e019307.	3.7	1
47	Improving the Prognosis in Patients With Diabetes: What Will ADVANCE Tell Us?. American Journal of Hypertension, 2007, 20, S19-S22.	2.0	0
48	A17615 Baseline predictors of all-cause- and cardiovascular- mortality amongst 8580 hypertensive patients followed up for 16 years in the ASCOT legacy study. Journal of Hypertension, 2018, 36, e251.	0.5	0
49	COMPARING THE DISCRIMINATIVE ABILITY OF DIFFERENT ELECTROGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY IN PREDICTING CARDIOVASCULAR EVENTS IN HYPERTENSIVE PATIENTS. Journal of Hypertension, 2021, 39, e165-e166.	0.5	0
50	INFLUENCE OF AGE, SEX AND AN OCCURRENCE OF CARDIOVASCULAR EVENT ON SEASONAL VARIATIONS IN BLOOD PRESSURES IN HYPERTENSIVE PATIENTS: INSIGHTS FROM THE ASCOT COHORT. Journal of Hypertension, 2021, 39, e145-e146.	0.5	0
51	THE DEVELOPMENT OF RESISTANT HYPERTENSION INDEPENDENT OF THE PRECEDING PERIOD OF THE BLOOD PRESSURE CONTROL IS ASSOCIATED WITH THE INCREASED RISK OF CARDIOVASCULAR EVENTS AND DEATH. Journal of Hypertension, 2021, 39, e358.	0.5	0
52	Blood Pressureâ€“Lowering Effects of Omegaâ€3 Polyunsaturated Fatty Acids: Are These the Missing Link to Explain the Relationship Between Omegaâ€3 Polyunsaturated Fatty Acids and Cardiovascular Disease?. Journal of the American Heart Association, 2022, 11, .	3.7	0